<SEC-DOCUMENT>0001193125-24-263398.txt : 20241121
<SEC-HEADER>0001193125-24-263398.hdr.sgml : 20241121
<ACCEPTANCE-DATETIME>20241121160702
ACCESSION NUMBER:		0001193125-24-263398
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241121
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241121
DATE AS OF CHANGE:		20241121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		241484285

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		302-274-8744

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d769907d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20241121" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-391">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-11-21_to_2024-11-21">0001937653</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="zyme-20241121.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-11-21_to_2024-11-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-21</xbrli:startDate> <xbrli:endDate>2024-11-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-402">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt:datemonthdayyearen" id="ixv-403">November 21, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-404">Zymeworks Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:stateprovnameen" id="ixv-405">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-406">001-41535</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-407">88-3099146</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:33%"/>
<td style="vertical-align:bottom"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-408">108 Patriot Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-409">Suite A</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-410">Middletown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:stateprovnameen" id="ixv-411">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-412">19709</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-413">(302)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-414">274-8744</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:boolballotbox" id="ixv-415">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:boolballotbox" id="ixv-416">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:boolballotbox" id="ixv-417">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:boolballotbox" id="ixv-418">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-419">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-420">ZYME</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:exchnameen" id="ixv-421">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-11-21_to_2024-11-21" format="ixt-sec:boolballotbox" id="ixv-422">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;21, 2024, Zymeworks Inc. (&#8220;Company&#8221;) issued a press release announcing, with Jazz Pharmaceuticals plc, that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) has granted accelerated approval of Ziihera&#174; (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (&#8220;BTC&#8221;). A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided under this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks BC Inc. (&#8220;Zymeworks&#8221;), a subsidiary of the Company, is a party to an Amended and Restated License and Collaboration Agreement (as amended, the &#8220;License and Collaboration Agreement&#8221;) with Jazz Pharmaceuticals Ireland Limited, a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as &#8220;Jazz,&#8221; granting Jazz exclusive rights to develop and commercialize Zymeworks&#8217; proprietary bispecific HER2 antibody product candidate known as zanidatamab throughout the world, but excluding certain territories already covered by Zymeworks&#8217; agreement with BeiGene, Ltd. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced on November&#160;21, 2024, the FDA granted accelerated approval of Ziihera&#174; (zanidatamab-hrii, a bispecific HER2-directed antibody that binds to two extracellular sites on HER2) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive BTC, as detected by an <span style="white-space:nowrap">FDA-approved</span> test. Ziihera&#174; was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review from the <span style="white-space:nowrap"><span style="white-space:nowrap">HERIZON-BTC-01</span></span> trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive BTC. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the ongoing Phase 3 <span style="white-space:nowrap"><span style="white-space:nowrap">HERIZON-BTC-302</span></span> confirmatory trial, evaluating zanidatamab in combination with <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> therapy versus <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> therapy alone in the first-line setting for patients with HER2-positive BTC. Zanidatamab is also being investigated in a number of additional tumor types, including Phase 3 trials in gastroesophageal adenocarcinomas and metastatic breast cancer. This approval represents the first <span style="white-space:nowrap">FDA-approved</span> therapy in the Company&#8217;s pipeline and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the License and Collaboration Agreement, Zymeworks has earned a milestone payment of $25&#160;million based on the FDA approval in BTC. Zymeworks remains eligible to receive up to $500&#160;million in regulatory milestone payments and $862.5&#160;million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz. For additional information regarding the License and Collaboration Agreement, please refer to the Company&#8217;s Current Reports on Form <span style="white-space:nowrap">8-K,</span> filed with the U.S. Securities and Exchange Commission on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001937653/000119312522264856/d399364d8k.htm">October<span style="text-decoration:underline"></span>&#160;19, 2022</a> and on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001937653/000119312523145682/d481028d8k.htm">May<span style="text-decoration:underline"></span>&#160;16, 2023</a>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Safety Information for Ziihera&#174; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:90%;border:0">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER:0.75pt solid #000000; padding-left:8pt; padding-right:2pt;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WARNING: EMBRYO-FETAL TOXICITY</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.</p></td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Embryo-Fetal Toxicity</span>. ZIIHERA can cause fetal harm when administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment with ZIIHERA and for 4 months following the last dose of ZIIHERA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Left Ventricular Dysfunction</span>. ZIIHERA can cause decreases in left ventricular ejection fraction (&#8220;LVEF&#8221;). LVEF declined by &gt;10% and decreased to &lt;50% in 4.3% of 233 patients. Left ventricular dysfunction (&#8220;LVD&#8221;) leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients. The median time to first occurrence of LVD was 5.6 months (range: 1.6 to 18.7). LVD resolved in 70% of patients. Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions. The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is below 50%. </p></td></tr></table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Infusion-Related Reactions</span>. ZIIHERA can cause infusion-related reactions (&#8220;IRRs&#8221;). An IRR was reported in 31% of 233 patients treated with ZIIHERA as a single agent in clinical studies, including Grade 3 (0.4%), and Grade 2 (25%). IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.4% of patients. IRRs occurred on the first day of dosing in 28% of patients; 97% of IRRs resolved within one day. Prior to each dose of ZIIHERA, administer premedications to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use. If an IRR occurs, slow, or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Diarrhea</span>. ZIIHERA can cause severe diarrhea. Diarrhea was reported in 48% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%). If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Withhold or permanently discontinue ZIIHERA based on severity. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Adverse Reactions </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Serious adverse reactions occurred in 53% of 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Serious adverse reactions in &gt;2% of patients included biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). A fatal adverse reaction of hepatic failure occurred in one patient who received ZIIHERA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The most common adverse reactions in 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA (&#8805;20%) were diarrhea (50%), infusion-related reaction (35%), abdominal pain (29%), and fatigue (24%). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Use in Specific Populations </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pediatric Use</span>. Safety and efficacy of ZIIHERA have not been established in pediatric patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Geriatric Use</span>. Of the 80 patients who received ZIIHERA for unresectable or metastatic HER2-positive BTC, there were 39 (49%) patients 65 years of age and older. Thirty-seven (46%) were aged <span style="white-space:nowrap">65-74</span> years old and 2 (3%) were aged 75 years or older. No overall differences in safety or efficacy were observed between these patients and younger adult patients. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d769907dex991.htm">Press Release, dated November&#160;21, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded as Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ZYMEWORKS INC.</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3" align="center">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;21, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Kenneth Galbraith</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kenneth Galbraith</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chair, President and Chief Executive Officer</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d769907dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g769907g1121141122429.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FDA Grants U.S. Approval of Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
(zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the
U.S.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ziihera received accelerated approval based on results including a 52% objective response rate and median
duration of response of 14.9 months as determined by independent central review (ICR) from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01</FONT></FONT> clinical trial</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>$25M milestone payment to be received from Jazz Pharmaceuticals in relation to the FDA approval; Zymeworks
remains eligible for up to $500M in regulatory milestones</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>U.S. FDA approval of zanidatamab provides validation of the Company&#146;s proprietary Azymetric</I><I><SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP></I><I> technology and capabilities for design and development of novel medicines</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Zanidatamab continues to be investigated in a number of additional tumor types, including Phase 3 trials in
gastroesophageal adenocarcinomas (GEA) and metastatic breast cancer (mBC)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vancouver, British Columbia (November 21, 2024)</B>
&#150; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Ziihera<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP><B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B>(zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or
metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> test.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP><I> Ziihera</I> was approved under accelerated approval
based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of
clinical benefit in a confirmatory trial.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> The approval of <I>Ziihera, </I>which previously received Breakthrough Therapy Designation from the FDA for this indication,<I> </I>is an important
advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland
Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as Jazz), for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories
except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the Company to leverage Jazz&#146;s global commercial infrastructure, together with BeiGene&#146;s complementary strengths in certain Asia Pacific
countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of
$25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This approval represents the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapy in Zymeworks&#146; pipeline, and validates the Company&#146;s
novel Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> bispecific platform technology and internal research and development capabilities for novel multifunctional medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The FDA&#146;s accelerated approval of <I>Ziihera</I> marks the culmination of more than a decade of research and development at Zymeworks, highlighting
our deep scientific expertise in multifunctional biotherapeutics and unwavering commitment to innovation in drug development,&#148; said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. &#147;This approval exemplifies our team&#146;s
exceptional scientific capabilities to translate from an initial hypothesis for dual-HER2 blockade to a breakthrough treatment that offers new hope for patients with unresectable or metastatic HER2-positive BTC with limited treatment options and few
approved therapies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through rigorous scientific investigation, innovative protein engineering, and proprietary Azymetric<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> bispecific platform technology, Zymeworks developed the unique binding mechanism of zanidatamab-hrii, which enables it to bind to two extracellular sites on HER2. Binding of zanidatamab-hrii
with HER2 results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular
phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA approval of <I>Ziihera</I> is based
on compelling data from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01</FONT></FONT> trial, which included the evaluation of zanidatamab as a single agent in previously treated HER2-positive (as determined by
Roche Diagnostic&#146;s PATHWAY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HER-2/neu</FONT></FONT> (4B5) Rabbit Monoclonal Primary Antibody companion diagnostic)
BTC and is the largest Phase 2b clinical trial to date specifically for this patient population. The trial achieved its primary endpoint of confirmed objective response rate (cORR) by independent central review (ICR) and results were presented at
the <U>American Society of Clinical Oncology (ASCO) Annual Meeting 2023</U>, published in <I><U>The Lancet Oncology</U></I><I>,</I> and included in the 2023 Best of ASCO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> program<I>.</I>
Longer <FONT STYLE="white-space:nowrap">follow-up</FONT> data showing improvement upon previously reported DOR were reported at the <U>ASCO Annual Meeting 2024</U>.<SUP STYLE="font-size:75%; vertical-align:top">1 </SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 3 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-302</FONT></FONT>
confirmatory trial is ongoing to evaluate zanidatamab in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapy versus
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> therapy alone in the first-line setting for patients with HER2-positive BTC. Zanidatamab is also being investigated in a number of additional tumor
types, including Phase 3 trials in gastroesophageal adenocarcinomas (GEAs) and metastatic breast cancer (mBC). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-GEA-01</FONT></FONT> trial is evaluating the potential of
zanidatamab plus chemotherapy with or without tislelizumab as first-line treatment for patients with advanced/metastatic HER2-positive GEAs and <FONT STYLE="white-space:nowrap">top-line</FONT> progression-free survival data from this study is
expected to be available in <FONT STYLE="white-space:nowrap">Q2-2025.</FONT> The <FONT STYLE="white-space:nowrap">EmpowHER-303</FONT> trial is evaluating the potential of zanidatamab in combination with physician&#146;s choice chemotherapy for the
treatment of HER2-positive mBC for patients who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our strategic
collaboration with Jazz provided the optimal &#145;partner of choice&#146; to continue the rapid advancement of zanidatamab, and we are extremely encouraged with Jazz&#146;s continued investment in and dedication to the development and
commercialization of this novel therapy within their geographic territories,&#148; said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. &#147;The combination of our strong balance sheet and anticipated revenue stream associated
with zanidatamab positions us to accelerate the development of our wholly-owned R&amp;D programs, while maintaining our projected cash runway into the second half of 2027.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks continues to advance a diverse pipeline of novel therapeutics targeting
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers and other serious diseases, with several product candidates in various stages of development. The Company&#146;s <FONT
STYLE="white-space:nowrap">in-house</FONT> research and development capabilities, which were instrumental in zanidatamab&#146;s success, remain focused on delivering the next generation of innovative treatments. Zymeworks will host an <FONT
STYLE="white-space:nowrap">in-person</FONT> and virtual R&amp;D day in New York on December&nbsp;12, 2024, which will feature updates on the Company&#146;s portfolio of solid tumor targeting antibody-drug conjugates and T cell engager molecules,
including preclinical progress supporting potential investigational new drug applications for multiple new product candidates in 2025, 2026 and beyond, and strategy and rationale for potential expansion into new therapeutic areas in hematological
cancers and autoimmune and inflammatory diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information about <I>Ziihera</I>, the Full Prescribing Information, including Boxed Warning and
Patient Information, is available <U>here</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (zanidatamab-hrii) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ziihera</I> (zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab-hrii with HER2
results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular
phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> In the United States, <I>Ziihera</I> is indicated for the treatment of adults with
previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> test.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> The U.S. Food and
Drug Administration (FDA) granted accelerated approval for this indication based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a
confirmatory trial(s).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is not approved anywhere else in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is
being developed by Jazz and BeiGene, Ltd. (BeiGene) under license agreements from Zymeworks, which first developed the molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA granted
Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy for 1L gastroesophageal adenocarcinoma (GEA). Additionally, zanidatamab has received Orphan Drug designations from FDA for the treatment of BTC
and GEA, as well as Orphan Drug designation from the European Medicines Agency for the treatment of BTC and gastric cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information about
<I>Ziihera</I>, the Full Prescribing Information, including Boxed Warning and Patient Information, is available <U>here</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety
Information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>WARNING: EMBRYO-FETAL TOXICITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective
contraception. </B></P></div> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WARNINGS AND PRECAUTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Embryo-Fetal Toxicity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZIIHERA can cause fetal harm when
administered to a pregnant woman. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal
death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of
reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment with ZIIHERA and for 4 months
following the last dose of ZIIHERA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Left Ventricular Dysfunction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF). LVEF declined by &gt;10% and decreased to &lt;50% in 4.3% of 233 patients. Left
ventricular dysfunction (LVD) leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients. The median </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time to first occurrence of LVD was 5.6 months (range: 1.6 to 18.7). LVD resolved in 70% of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of
adverse reactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is below 50%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Infusion-Related Reactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZIIHERA can cause
infusion-related reactions (IRRs). An IRR was reported in 31% of 233 patients treated with ZIIHERA as a single agent in clinical studies, including Grade 3 (0.4%), and Grade 2 (25%). IRRs leading to permanent discontinuation of ZIIHERA were reported
in 0.4% of patients. IRRs occurred on the first day of dosing in 28% of patients; 97% of IRRs resolved within one day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to each dose of ZIIHERA,
administer premedications to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs
available for immediate use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an IRR occurs, slow, or stop the infusion, and administer appropriate medical management. Monitor patients until complete
resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diarrhea
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZIIHERA can cause severe diarrhea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diarrhea was
reported in 48% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%). If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other
causes of diarrhea. Withhold or permanently discontinue ZIIHERA based on severity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADVERSE REACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Serious adverse reactions occurred in 53% of 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA. Serious adverse reactions in
&gt;2% of patients included biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). A fatal adverse reaction of hepatic failure occurred in one patient
who received ZIIHERA. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most common adverse reactions in 80 patients with unresectable or metastatic HER2-positive BTC who received ZIIHERA (&#8805;20%)
were diarrhea (50%), infusion-related reaction (35%), abdominal pain (29%), and fatigue (24%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USE IN SPECIFIC POPULATIONS </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pediatric Use </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Safety and efficacy of ZIIHERA have not been established in pediatric patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Geriatric Use </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the 80 patients who received ZIIHERA
for unresectable or metastatic HER2-positive BTC, there were 39 (49%) patients 65 years of age and older. Thirty-seven (46%) were aged <FONT STYLE="white-space:nowrap">65-74</FONT> years old and 2 (3%) were aged 75 years or older. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No overall differences in safety or efficacy were observed between these patients and younger adult patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biliary Tract Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BTC, including gallbladder
cancer and intrahepatic and extrahepatic cholangiocarcinoma, account for &lt;1% of all adult cancers globally and are often associated with a poor prognosis.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><SUP
STYLE="font-size:75%; vertical-align:top">,</SUP><SUP STYLE="font-size:75%; vertical-align:top">3</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP>The human epidermal growth factor receptor 2 (HER2) is a well-validated target for antitumor
therapy in other cancers. Across the U.S., Europe, and Japan, approximately 12,000 people are diagnosed with HER2+ BTC annually.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP
STYLE="font-size:75%; vertical-align:top">5</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP STYLE="font-size:75%; vertical-align:top">6</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP
STYLE="font-size:75%; vertical-align:top">7</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is a heterodimeric antibody technology that gives the ability to engineer, screen, and
effectively choose the optimal geometry and valency for our targeted treatments. These customized therapeutic antibodies are engineered to simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique
mechanisms of action not accessible through typical monospecific antibodies. Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> antibodies can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor
clustering and internalization, and increase tumor-specific targeting. Zymeworks&#146; other technologies can combine with Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> to engineer the antibody backbone of a bispecific
antibody-drug conjugate or the base of a multispecific therapeutic, to overcome known therapeutic barriers and help design potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> <FONT
STYLE="white-space:nowrap">bi-specifics</FONT> and trispecifics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
biotherapeutics. Zymeworks&#146; mission is to make a meaningful difference in the lives of people impacted by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers and other diseases. The
Company&#146;s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Valle JW, et al. Lancet 2021; <FONT STYLE="white-space:nowrap">397:428-44</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Siegel RL, et al. CA Cancer J Clin 2022; <FONT STYLE="white-space:nowrap">72;7-33</FONT> </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BTC overall diagnosed patients as per SEER 22 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes anatomic subsites intrahepatic CCA, extrahepatic CCA, gallbladder cancer, and BTC unspecified
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes HER2 positivity rates per anatomical subsite from: Galdy, S., Lamarca, A., McNamara, M.G. et al. Cancer
Metastasis Rev 36, 141&#150;157 (2017), Nobuyoshi Hiraoka, et al. Human Pathology, Volume 105, 2020, Pages <FONT STYLE="white-space:nowrap">9-19</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Major markets: U.K, France, Germany, Spain, Italy. Note: HER2+ BTC patients in Jazz-controlled commercial
territories, which includes Japan, and excludes other certain Asia Pacific countries licensed to BeiGene, Ltd </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company&#146;s proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology.
Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently
being evaluated in multiple global clinical trials as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for patients with HER2-expressing cancers. The U.S. FDA granted accelerated
approval of Ziihera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B>(zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with
previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC).<I> Ziihera</I> is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. A BLA has also been accepted for
review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug
conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251
planned for 2025. In addition to Zymeworks&#146; pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit <U>www.zymeworks.com</U>
and follow <U>@ZymeworksInc</U> on X. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#147;forward-looking statements&#148; or information within the meaning of the applicable securities legislation, including
Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the
conduct of an ongoing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-302</FONT></FONT> Phase 3 confirmatory trial to evaluate the efficacy and safety of zanidatamab and support global registration; ongoing clinical
studies and regulatory reviews; the anticipated benefits of the collaboration agreements with Jazz and BeiGene, including Zymeworks&#146; ability to receive any future milestone payments and royalties thereunder; the potential addressable market of
zanidatamab; the timing of and results of interactions with regulators; Zymeworks&#146; clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies and the related data;
expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab and Zymeworks&#146; other product candidates; the commercial potential of technology platforms and
product candidates; Zymeworks&#146; ability to satisfy potential regulatory and commercial milestones with existing and future partners; anticipated continued receipt of revenue from existing and future partners; anticipated sufficiency of existing
cash resources and certain anticipated revenues from zanidatamab to fund Zymeworks&#146; planned operations into the second half of 2027; Zymeworks&#146; ability to execute new collaborations and partnerships and other information that is not
historical information. When used herein, words such as &#147;plan&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;may&#148;, &#147;anticipate&#148;, &#147;potential&#148;, &#147;will&#148;, &#147;continues&#148;, and similar expressions are
intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are
based upon Zymeworks&#146; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs
may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks&#146; or its partners&#146; product
candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations;
regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; the impact of pandemics and other health crises on Zymeworks&#146; business,
research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#146; behalf; zanidatamab may not be successfully
commercialized; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#146; or its collaborators&#146; product candidates; Zymeworks&#146; assumptions and estimates regarding its financial
condition, future financial performance and estimated cash runway may be incorrect; and Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not
place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no
obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Inquiries: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shrinal Inamdar </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@zymeworks.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Inquiries: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT STYLE="white-space:nowrap">678-1388</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@zymeworks.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zyme-20241121.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/21/2024 9:36:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:zyme="http://www.zymeworks.com/20241121"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.zymeworks.com/20241121"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20241121_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20241121_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>zyme-20241121_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/21/2024 9:36:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>zyme-20241121_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/21/2024 9:36:00 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20241121.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g769907g1121141122429.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g769907g1121141122429.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I .D# 2(  A$! Q$!_\0
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MJ@UMIH&D1W7VE--M5FSG>(QFM&OKL5C?;1Y4K&>&P?L9<S=PHHHK@.X****
M"BBB@ HHHH **** "DI:2@!:*8\T46/,D1,]-S 4S[7;?\_$7_?8J7**W8$U
M%1+<P,<+-&3C/#"E2XAD;:DT;'T# T<T>X$E%(2%!+$ #J34:W$#G"S1L>N
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M.V*FG\/Z>D>_P]XCF34%(,:O>[E;U!%16^K^ 9K=)+^RMK>[*CS8FMF&UN_
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@ 4444 %%%% !1110 4444 %%%% !1110 4E+24 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45943810523456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 21,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( ." =5DD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #@@'5999!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ X(!U6>.&:OWN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ X(!U69E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #@@'59D3[-85P$   J$0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ X(!U69^@&_"Q
M @  X@P   T              ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #@@'59EXJ[',     3 @  "P              @ %[#P  7W)E;',O
M+G)E;'-02P$"% ,4    " #@@'59'#AEZC\!   \ @  #P
M@ %D$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ X(!U620>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ X(!U6660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d769907d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d769907d8k.htm">d769907d8k.htm</File>
    <File>zyme-20241121.xsd</File>
    <File>zyme-20241121_lab.xml</File>
    <File>zyme-20241121_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d769907d8k.htm": {
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20241121",
   "dts": {
    "inline": {
     "local": [
      "d769907d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "zyme-20241121.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20241121_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20241121_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-11-21_to_2024-11-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d769907d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-11-21_to_2024-11-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d769907d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zymeworks.com//20241121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-263398-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-263398-xbrl.zip
M4$L#!!0    ( ." =5E+L\&$DAL  +"D   .    9#<V.3DP-V0X:RYH=&WM
M7>USXCC2_YZ_0L7N[)*J\&(#"9 ,5TR2F>793)(BV=N]^;(E; ':,;9/MI.P
M?_W3W;*->0LD@61FCZN[FX!EJ=7JEU^W6N+D7P\CA]T)%4C/??^S42S_S(1K
M>;9T!^]_;M^<=CH__ZNU=S(,H1DT=8.F+>3[W# ,_6:I]-!33C$05G'@W97@
M0<DLFY5<W# *"N'8%T':NL^#7M%3@U+R9*JYZ[EN-$H;W]_?%ZE[?,$.50G?
M*$&C K022EK)>P^.=+].O79?H9>,1J-1HJ=)T[F6Z0!FN5PIX>,>#T32_._Q
M2$PUQR_N/?4U*%K>"(FO&H9II(0$<A$9T+51^N/SQ8TU%"->D&X0<M=*!XE"
MM92D1@F>)@UEX%5-X^@1^N,6Z0L/R]H:T-:%V8H_/G0O)LW#Q>TG34NAXF[0
M]]2(AR OV%.M4#8+YF&FDP+(PU1'B7RLZJ=>J$QX"8/+QZ8ZPT5\:L_(9=SX
ML*0?QDV72PK*> YE77 ;_@EEZ(A6O?#K24G_N7<R$B%G^'I!_#>2=^]SIYX;
M"C<LW()LYIBE/[W/A>(A+%%W)7BKI#MDC)WT/'O<.K'E'0O"L0/"9<O =_@8
MA5_D6NQ$/C2QM5#QW]*VA:O_AB:76O*9RU$P0=^:[9%P;?A?^-'A@YB"A[ K
M^O X4L3=/U%."X91,(T_0R_S*<>D_3XG'^X*E8:1:_6Y$XB3TM1(<R/C&[\0
M47_"\'^>N\":\2F,K[C3<6WQ\*L8YS+T+6GP-#I;95"A1N7HL%:9IZ\TPR8E
M^D*!"1,!?$:-;@:D>##6-@T&C80FZGTND"/?2;\;*IPD6HY"8C"*#X&=/.;*
M4IXCUAFD%,]V:H;T.? BI3^2WC1C]M)JK<'>Y#5!BY5^E#9^T9=",6*A6*C5
MIYU?IQ=H]F6D>F'_/JR@9Z<?0:%5>,9#T9K0EKPY>3:AU5[2-GF2#IN.4YKB
M3LK-"?=*6?4K@9K"/QEEQ;<*W)$#MVG!7(3*33^_EW8X;-:+->D>9]HZHA\>
MC[@:2+> ?S<9CT(O^4;)P3#^"KOSD\[05A:&@IZ"6_;3+D+/;V8^]KPP]$;T
M3<]30'KRC>$_L,!SI,U^*--_<JV??C .R\<G)7_90)75 YG/'BC3;14Z8?,3
M8'U8FD(@_Q9-HYY^[O.1=,;-6SD2 ;L4]ZSKC;A[3,_N-=T]S[&/%RS/;Y>=
MV_,S=G/;OCV_64Y.^97(N3D__:W;N>V<W[#VY1D[_^/TE_;EIW-V>O7Y<^?F
MIG-U^2(:S4W0^#L/A@#^0L\]8&?%TR(SR[5J8X:NF4%72>:T0*S2J(62>?@L
MR2R6H=FT<!YK+36-=_.S7U-+)Y-)C,2B!=/+\0I2]?&J^YF=!#YW4T,TE*$H
MP#>6 &=YK[B?:RV%$&>>%2&"R&"8IR.(:MG,::PT[9]/2DA7:R<^6Q&?C2@\
MF*3N^>4MZYY?7W5OW]X 74<JB+@;LM!C-\)" 61&A7F*&;6\O?_V!'I]%@X%
MTA8I&4IX__S!&G)W(%C;"AD\!BQ474[GJZTLPB DIRM\3X4LGWP6'&"0"$(F
M[J E4_18V/O-Y7%&8B2N"4N=:XCU9&NA(SZT&&'3A@Y&\/K0YN,Q4"3<K#6I
MY%J7WIT8]0!\FL8!PU[F;<O.J&S>J)C538C>4D'2 6%7#&2 28#P$IZ\P.M4
M<ZTO25*&=5RKN$)(GF8NRIM@1?[\@8-90!:@\JETZHP'+/"%A5&2S:3+9!@P
M,"2@BVK6S.V$>XEPOX0Q>R<A[SF"6<)Q$"QASC-7SM%GG]MV\CD>*IZJY3D.
M]P/13/YX7$0R\H1H3S/#*)??Q:QKEF,JF^4D" 2Z%/V_/1U95JKO, F0?7 G
M5"@M[L1<U1.=;12_;:[W=D+B7.ML-R>EF$25//7Y0!1Z2O"OF.*$\+_)[SR0
M@K6Y8]#R3(W(,@+#IB2F2;+"9B8 RPZF)XN$9Q5TI64"&^(I\(=D@FY"<%*G
M7N2&:GSJV2]R>)@6Q3Q&*'SEW>&PTQZO!OY:./P>/.%2$!W:ZZQ^*N*SS=^
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M D&"4,YQ"!OT!.!=@!PVBWG?EXZP8^Z3#( GAU435,LX[<GK:T+4 UP9/M+
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MF*$4?0#XR<_<7]'/W*ME5P)\E[%N=4FL>U+"0^#P>1B.G-;_ U!+ P04
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MW8/]?0T_+7ZF7D-\/<8G<4?B0V<KZ.7"]BFYD6FJD"-.RQJF\350+(BH5-5
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MMKKV$/[<J1V2T20#IU]&%B8>Q1#K5[FH07H0<C?I7V4 B.44XT:Q&$F.)8G
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MT;/BJ"7X4BG;L[4-BTO#1+4,C!(X!'V^<)Z&DWH9Q"^H7LHR,&)V1HFV$#F
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M:CY10<&?'OP.'WZ^/#[:_5]02P,$%     @ X(!U6?LXX!9  P  4 L  !$
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M0^RWXG08C]*$C$6@[J6]HX; GDRDJ^ZCB*Q;XV B=E<+^T7L%[N\W]_XC\[
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MY=C^]B/UT,@Q)5/AJ0K0-HIT][_[R[]3&<G.R8?-(H)'(B3E[+0SZ/8[0%C
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M^#+,S,O-80S1)8W(I]5B2D2]B2GFM3H>!@/<?-P=_.=:N)1K=4CED8#&[M=
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MB^-[ +5!0?PZP._FM/4.0%/C?/^8T_O_]G20P$W^G]?*.)SB][GSWC_+9MU
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MD!-+_@902P$"% ,4    " #@@'592[/!A)(;  "PI   #@
M@ $     9#<V.3DP-V0X:RYH=&U02P$"% ,4    " #@@'59\),7SZ0G  "Q
MJP  $0              @ &^&P  9#<V.3DP-V1E>#DY,2YH=&U02P$"% ,4
M    " #@@'59^SC@%D #  !0"P  $0              @ &10P  >GEM92TR
M,#(T,3$R,2YX<V102P$"% ,4    " #@@'596^ 68'H&  "Z1@  %0
M        @ $ 1P  >GEM92TR,#(T,3$R,5]L86(N>&UL4$L! A0#%     @
MX(!U69' ZN'#!   0BP  !4              ( !K4T  'IY;64M,C R-#$Q
@,C%?<')E+GAM;%!+!08     !0 % $ !  "C4@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d769907d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20241121.xsd" xlink:type="simple"/>
    <context id="duration_2024-11-21_to_2024-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-391">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-11-21_to_2024-11-21"
      id="Hidden_dei_EntityCentralIndexKey">0001937653</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-402">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-403">2024-11-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-404">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-405">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-406">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-407">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-408">108 Patriot Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-409">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-410">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-411">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-412">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-413">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-414">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-415">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-416">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-417">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-418">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-419">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-420">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-421">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-11-21_to_2024-11-21" id="ixv-422">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
